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Epidermolysis bullosa simplex (EBS) is a rare genetic
condition typified by superficial bullous lesions
following incident frictional trauma to the skin. Most
cases of EBS are due to dominantly acting mutations
in keratin 14 (K14) or K5, the type I and II intermediate
filament (IF) proteins that copolymerize to form a
pancytoplasmic network of 10 nm filaments in basal
keratinocytes of epidermis and related epithelia. Defects
in K5–K14 filament network architecture cause basal
keratinocytes to become fragile, and account for their
rupture upon exposure to mechanical trauma. The
discovery of the etiology and pathophysiology of EBS
was intimately linked to the quest for an understanding
of the properties and function of keratin filaments in
skin epithelia. Since then, continued cross-fertilization
between basic science efforts and clinical endeavors
has highlighted several additional functional roles for
keratin proteins in the skin, suggested new avenues
for effective therapies for keratin-based diseases, and
expanded our understanding of the remarkable pro-
perties of the skin as an organ system.
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INTRODUCTION
The discovery of the genetic basis for the inherited bullous
disease epidermolysis bullosa simplex (EBS), made 20 years
ago, provided a new and paradigm-shifting blueprint for the
characterization and understanding of a large number of
monogenic disorders with a significant impact on skin. Since
then, EBS and related genetic conditions have continued to
provide a breeding ground for the cross-fertilization of ideas
and successes between basic science endeavors and clinical
findings. After a brief introduction to keratins, we here review
the clinical features of EBS, the discovery of its genetic basis,
and our current understanding of phenotype–genotype cor-
relations in this genodermatosis. We briefly discuss the nu-
merous roles assigned so far to keratin proteins and/or filaments
in skin epithelia, address the challenge of devising effective
therapies for EBS and related conditions, and finally, identify a
few important priorities for the future.
A PRIMER ON KERATIN INTERMEDIATE FILAMENTS
Keratins are the most abundant structural proteins in the cy-
toplasm of epithelial cells, in which they form a network of
10–12 nm wide intermediate filaments (IFs; Figure 1a–c)
(Fuchs and Cleveland, 1998; Kim and Coulombe, 2007). Keratin
proteins are encoded by a large family of conserved genes,
numbering B54 in the human genome (Schweizer et al.,
2006), which partition to the type I and II subgroupings of
IF-encoding genes. There are 28 type I (K9–K28; K31–K40)
and 26 type II (K1–K8; K71–K86) genes, each coding for one
polypeptide chain (Schweizer et al., 2006). Type I proteins
tend to be smaller (40–64 kDa) and more acidic (pIB4.7–6.1)
than the larger (52–70 kDa) and basic–neutral (pI B5.4–8.4)
type II proteins (Moll et al., 1982; Schweizer et al., 2006).
Keratin polymerization obligatorily begins with the formation
of coiled-coil heterodimers involving one type I and one type
II protein (Steinert et al., 1976; Fuchs and Cleveland, 1998;
Kim and Coulombe, 2007). This requirement underlies the
pairwise transcriptional regulation of keratin genes in vivo
(Moll et al., 1982; O’Guin et al., 1990; Fuchs, 1995). Furthermore,
the regulation of keratin genes, individually or as pairs, depends
upon the type of epithelia, stage of cellular differentiation,
and context (such as disease) (Moll et al., 1982; O’Guin et al.,
1990; Fuchs, 1995; Freedberg et al., 2001). Keratin genes and
proteins thus provide unparalleled molecular markers to track
the status of epithelial cells in health and disease.
In Homo sapiens, the functional type I and type II keratin
genes are clustered on the long arms of chromosomes 17 and
12, respectively, the sole exception being the K18 locus
(located next to its partner gene K8 on the type II cluster).
Whole-genome sequencing has confirmed that the genomic
organization, sequence, and regulation of keratin genes are
conserved among mammals (Coulombe and Bernot, 2004;
Hesse et al., 2004; Schweizer et al., 2006). In addition to
the large number of keratin genes (Schweizer et al., 2006),
the promiscuity with which type I and II keratin proteins
pair up and polymerize with one another (Hatzfeld and
Franke, 1985) generates a tremendous potential for diversity
in the surface chemistry of keratin filaments in living cells.
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The latter remains underappreciated as there is yet no
high-resolution structural insight into the core architecture of
keratin filaments.
An astounding two-thirds of known keratin genes are
expressed in skin epithelia alone. In normal interfollicular
epidermis, progenitor basal cells express the K5–K14 pair,
and small amounts of K15 protein (Nelson and Sun, 1983;
Lloyd et al., 1995; Porter et al., 2000). Upon commitment to
differentiation, keratinocytes rapidly turn on the expression of
K1–K10 (Fuchs and Green, 1980; Woodcock-Mitchell et al.,
1982) as they switch off K5–K14 gene transcription (although
the proteins persist; Figure 1d–f; Fuchs, 1995). At a later stage,
i.e., in the granular layer, K2e gene expression occurs (Collin
et al., 1992). These specific switches in keratin gene expres-
sion have been highly conserved throughout evolution, and
are paralleled by striking changes in the density and organi-
zation of keratin IFs in keratinocytes (Figure 1g). This basic
blueprint can be altered to reflect regional specialization
(e.g., palmoplantar epidermis) or a departure from normal
differentiation. For instance, K9 is prominently expressed
post-mitotically in the thick ‘‘primary epidermal ridges’’ of
palmar and plantar epidermis, whereas K6, K16, and K17
occur in the thinner, ‘‘secondary ridges’’ connecting them
(Swensson et al., 1998). Otherwise, K6, K16, and K17 are
induced, generally at the expense of the K1–K10 pair, in the
post-mitotic layers of interfollicular epidermis under conditions
of environmental challenges (e.g., tissue injury, UV exposure,
and viral infection) and in specific diseases (e.g., psoriasis and
carcinoma) (O’Guin et al., 1990; McGowan and Coulombe,
1998; Freedberg et al., 2001). Evidence in hand suggests that
although keratin proteins do not affect the execution of differ-
entiation, the maintenance of a specific complement of keratin
proteins has an important role toward cytoarchitecture
and several cellular functions in differentiated or specialized
epithelial states.
EBS: A RARE, DEVASTATING, BUT INSTRUCTIVE
GENODERMATOSIS
EB corresponds to a group of rare genetic conditions in which
bullous lesions affecting primarily the skin arise after exposure
to mechanical trauma. Three major forms of EB have been
defined. The dystrophic, junctional, and simplex forms of EB
are characterized by loss of tissue integrity in the upper dermis,
at the dermo–epidermal interface, and within the epidermis,
respectively (Figure 2a; Fine et al., 2008). EBS (Figure 2b) is
the most frequently occurring, and least severe, form of EB
disease (B1 case per 25,000 live births), and is inherited in
an autosomal dominant fashion with rare exceptions (Fine
et al., 2008; Szeverenyi et al., 2008; Coulombe et al., 2009).
In EBS, trauma-induced loss of tissue integrity occurs within
the basal layer of epidermal keratinocytes (Figures 2a and 3).
The genetic defect renders basal keratinocytes fragile, causing
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Figure 1. Keratin filaments: structure, organization, and expression in the interfollicular epidermis. (a) Schematic representation of the common domain
structure shared by intermediate filament (IF) proteins, including keratins. A central domain, comprising a-helical coils 1A, 1B, 2A, and 2B separated by non-
helical linkers L1, L12, and L2, is flanked by head and tail domains of unknown structure at its N- and C-termini. The boundaries of the rod domain (see red
boxes) are highly conserved in primary structure. (b) Visualization of filaments, reconstituted in vitro from purified human keratin 5 (K5) and keratin 14 (K14), by
negative staining and electron microscopy. Bar¼150 nm. (c) Double labeling for keratin (red chromophore) and desmoplakin, a desmosome component (green
chromophore), epitopes in human epidermal keratinocytes in culture. Keratin IFs are organized in a network that spans the entire cytoplasm and are attached at
desmosomal cell–cell contacts between cells (arrowheads). n, nucleus. Bar¼ 50mm. Micrograph courtesy of Dr K Green (Northwestern University, Chicago, IL).
(d) Histological cross-section of resin-embedded human trunk epidermis, revealing the basal (B), spinous (S), granular (G), and cornified (C) cell layers.
Bar¼50 mm. n, nucleus. (e, f) Differential distribution of keratin epitopes in the human epidermis. (e) K10 occurs in the suprabasal, differentiating keratinocytes
of the epidermis. Basal lamina is depicted by a dashed line. Bar¼ 50mm. (f) K14 occurs in the basal layer, where the epidermal progenitor cells reside.
(g) Ultrastructure of the boundary between the basal and suprabasal layers in mouse trunk epidermis, as seen in the cross-section by routine transmission
electron microscopy. Organization of keratin filaments as loose bundles correlates with the expression of K5–K14 in basal cells (see brackets), whereas the
formation of denser, electron-dense filament bundles reflects the onset of K1–K10 expression in early differentiating cells (see arrowheads). Arrows point to
desmosomes. Bar¼2 mm. n, nucleus. Adapted from Miller et al. (2008).
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them to ‘‘rupture’’ when the epidermis (and, in some cases,
other stratified epithelia) is subjected to mechanical trauma.
The rupture of basal keratinocytes often occurs in a specific
area of the cell, between hemidesmosomes and the nucleus,
in the epidermis of EBS individuals (Haneke and Anton-
Lamprecht, 1982) and in relevant mouse models (Coulombe
et al., 1991a) (Figure 3), a phenomenon that remains un-
explained. Skin pigmentation anomalies can occur in EBS
(Gu and Coulombe, 2007; Fine et al., 2008); however, terminal
keratinocyte differentiation and epidermal barrier function are
reportedly normal in the untraumatized skin of EBS patients.
Several clinical variants of EBS have been described (note
that the new nomenclature for EBS is being used here; Fine
et al., 2008). The most frequent, and better understood,
variants are EBS-generalized (EBS-gen; in which blistering is
‘‘generalized’’ over the body), EBS-localized (EBS-loc; in
which blistering is largely restricted to hands and feet), and
EBS-Dowling-Meara (EBS-DM, in which blisters are generalized
as well, but show a distinct ‘‘herpetiform’’ or clustered pattern).
The main clinical findings distinguishing these three variants
are the distribution, frequency, and severity of skin blistering
over the body (Table 1), the ultrastructural features of basal
keratinocytes, involvement of other epithelia, and prognosis
(Table 1). Additional forms of EBS are not only less frequent
but also tend to exhibit additional clinical features (Table 1;
see also Fine et al., 2008). For instance, EBS, autosomal
recessive, resembles the generalized form but is recessively
inherited, EBS with mottled pigmentation features ano-
malies in skin pigmentation, and EBS with muscular
dystrophy is accompanied by a progressive, limb-girdle
type of muscular dystrophy (Table 1; Omary et al., 2004;
Fine et al., 2008).
Despite the degree to which clinical presentation varies
(Fine et al., 2000, 2008; Horn and Tidman, 2000; Paller, 2004;
Table 1), all variants of EBS are caused by genetic mutations
in intracellular proteins, compromising their ability to provide
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Figure 2. Introduction to epidermolysis bullosa simplex (EBS). (a) Schematic representation of skin tissue (left) and detailed view of the bottom portion
of the epidermis (right), highlighting the cytoplasmic network of keratin intermediate filaments (IFs; light green) attached to hemidesmosome cell–extracellular
matrix (ECM; grey) and desmosome cell–cell (magenta) contacts in basal keratinocytes. Arrows depict the plane of tissue rupture seen in the ‘‘simplex,’’
‘‘junctional,’’ and ‘‘dystrophic’’ forms of epidermolysis bullosa (EB). (b) Example of trauma-induced bullous skin lesions (arrows) in the feet of a 2-month old
child diagnosed with bullosa simplex (EBS). Picture kindly provided by Dr Bernard Cohen (Johns Hopkins School of Medicine; see http://
dermatlas.med.jhmi.edu). Adapted from Coulombe et al. (2009).
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Figure 3. Loss of keratin 14 (K14) elicits epidermolysis bullosa simplex (EBS)-like features in newborn mouse skin. (a, b) Picture of newborn mouse littermates,
comparing K14-null and wild-type (WT) mice. (a) The K14-null neonate exhibits massive skin blistering. Front paws and facial area are severely affected
(see arrows). (b) A wild-type littermate exhibits intact skin. (c, d) Micrographs from hematoxylin/eosin-stained histological sections prepared from front paws of
2-day-old (c) K14-null and (d) WT mice. Epidermal cleavage is obvious in the K14-null sample. Loss of epidermal integrity occurs ‘‘near’’ the basal layer of
keratinocytes (see ‘‘blister’’), the defining characteristic of EBS. Three basal keratinocytes are boxed in d. epi, epidermis; hf, hair follicle. Bar¼ 100 mm. Adapted
from Coulombe et al. (2009).
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structural support in keratinocytes of the epidermis and related
tissues (Gu and Coulombe, 2007; Szeverenyi et al., 2008;
Coulombe et al., 2009). The vast majority of EBS cases are
due to mutations affecting either K14 or K5, which, as
mentioned above, are type I and II IF genes, selectively
expressed in basal keratinocytes in the epidermis and related
complex epithelia (Fuchs, 1995; Figure 1). Because of the
complex substructure of keratin filaments, the perturbations
engendered by mutations altering the primary structure of
either K5 or K14 proteins for the structure, organization, and/
or regulation of filaments can range from the very subtle to
the very severe, thereby accounting for a substantial
fraction of the broad clinical spectra typifying EBS (see
below). EBS with muscular dystrophy is caused by
mutations in plectin (Gache et al., 1996; McLean et al.,
1996), a cytolinker protein responsible for integrating
various cytoskeletal and cell adhesive elements into a
functionally unified network (see Table 1; Wiche, 1998).
The presence of plectin in hemidesmosomes of basal
epidermal keratinocytes and at the Z-lines of skeletal
myocytes account for the involvement of both skin and
muscle in EBS with muscular dystrophy (Wiche, 1998).
Mutations in type XVII a1 collagen (COL17A1), a hemi-
desmosomal plaque protein required for tight adherence of
basal keratinocytes to the basal lamina, account for a subset
of patients featuring elements typical of both EBS and EB
junctional (Fontao et al., 2004; Pfendner et al., 2005;
Figure 2a). Additional examples of rare forms of EBS linked
to genes other than K5 and K14 are discussed in the study
of Fine et al. (2008).
Table 1. Epidermolysis bullosa simplex (EBS) and other diseases caused by mutations in keratin 5 (K5) or keratin 14
(K14)
EBS variant1 Distinguishing features1 Onset Target genes
Orig. clinical
description
EBS, localized Formerly known as ‘‘Weber-Cockayne’’-type
EBS. Blistering usually limited to hands and feet,
but can occur at sites of repeated trauma; often
associated with palmoplantar keratoderma;
worsens in warmer months
Infancy, early
childhood,
adulthood
Most frequently K5;
less frequently K14
Weber (1926);
Cockayne (1938)
EBS, generalized Formerly known as ‘‘Koebner’’-type EBS. Blisters
predominantly on hands and feet but blistering is
often generalized; absence of large tonofilaments
in basal keratinocytes on electron microscopy;
worsens in warmer months
Birth or infancy K5 (C-terminal
region and L2 linker
domain); K14
Koebner (1886)
EBS-DM
(Dowling-Meara)
This form of EBS retained its original designation.
Widespread and severe blistering; herpetiform and
hemorrhagic blisters; frequent mucosal involvement;
progressive palmoplantar keratoderma; nail dystrophy
and milia; hyperpigmentation and hypopigmentation
may occur; may improve with heat or fever
Birth K5, K14 (at N- or
C-terminal ends
of the rod domain)
Dowling and
Meara (1954)
EBS-AR
(autosomal
recessive)
Very rare variant. Largely similar to the generalized form,
although the frequency of blistering may be less
Infancy K14 Hovnanian et al. (1993)
provided the first
mutation report
EBS-MP (with
mottled
pigmentation)
Skin blistering with mottled pigmentation of
trunk and limbs; punctate palmoplantar
keratoderma; nail dystrophy
Birth or infancy K5 (Pro24-4Leu
mutation in head
domain); K14
Fischer and
Gedde-Dahl (1979)
EBS-MD (with
muscular
dystrophy)
EBS-like skin blistering with progressive limb-girdle
muscular dystrophy. Very rare variant
Infancy Plectin Niemi et al. (1988)
EBS-Migr
(migratory)
Formerly known as EBS with migratory circinate
erythema. Annular migratory multiple erythema
circinatum; multiple vesicles on the hands, feet,
and legs; lesions heal with brown pigmentation
but no scarring. Very rare variant
Birth K5 (tail domain) Gu et al. (2003)
DDD (Dowling-
Degos disease)
Reticular hyperpigmentation on flexure surfaces After puberty K5 haploinsufficiency Dowling and
Freudenthal (1938)
NFJS (Naegeli–
Franceschetti–
Jadassohn
syndrome)
Reticular hyperpigmentation that disappears over time;
hypohydrosis; palmoplantar keratoderma; absent fingerprint
lines
Birth K14 (head domain) Naegeli (1927);
Fransceschetti and
Jadassohn (1954)
1This table is adapted from Coulombe et al. (2009). Additional EBS subtypes, caused by mutations in genes other than K5 and K14, are more rare. See Fine
et al. (2008) for a classification of all EBS variants.
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EARLY 1990S: A FUNCTION FOR KERATIN FILAMENTS
AND A PROMISING LEAD FOR THE ETIOLOGY OF EBS
By the late 1980s, several mechanisms had been proposed
to account for the etiology of EBS and the fragility of basal
keratinocytes that typifies this condition. These mechanisms
could be assigned to either one of two broadly defined
categories: a misregulated or defective enzyme or a defect in
a structural component (reviewed in Coulombe and Fuchs,
1993). With the notable exception of Dr Anton-Lamprecht
(Anton-Lamprecht, 1983), the literature suggests that no one
was considering the possibility of defects in keratin protein or
filaments in this condition. Given the heterogeneity in EBS
clinical features (Table 1) and the absence of a clear un-
derstanding of keratin filament function at the time, there was
no obvious reason to draw a link between the disorder and
keratin filaments. In the early 1990s, however, the combina-
tion of a reverse genetic approach with the transgenic mouse
technology provided key clues about the etiology of EBS (and
related genodermatoses), in addition to revealing a key function
for keratin filaments in their natural setting (Coulombe et al.,
1991b; Vassar et al., 1991; Fuchs et al., 1992).
The cloning and sequencing of (human) keratin genes, and
the resulting ability to better define the secondary structure of
their protein products (see, e.g., Fuchs et al., 1981; Hanukoglu
and Fuchs, 1982; Steinert et al., 1983), set the stage for
subsequent efforts aimed at defining the key determinants in
K14 and K5 coassembly using systematic deletion mutagen-
esis. Initial studies of this kind revealed that K14 deletion
mutants missing small portions of either end of the central rod
domain had a significant, and biochemically dominant, impact
on the organization of keratin filaments when expressed in
cultured epithelial cells (Albers and Fuchs, 1987, 1989). Im-
portant details about the impact and mode of action of such
K14 deletion mutants (Coulombe et al., 1990) and, later on,
K5 deletion mutants (Wilson et al., 1992) were subsequently
provided by in vitro polymerization assays making use of
purified recombinant keratin proteins. Relevance to EBS, and
to keratin function in vivo, was ultimately revealed when
select K14 deletion mutants were tissue-specifically expressed
in transgenic mice using the K14 promoter (Coulombe et al.,
1991b; Vassar et al., 1991). Mutant K14-expressing transgenic
mice exhibited trauma-induced blistering in the epidermis and
oral mucosa, beginning at or shortly after birth, in a manner
that closely approximated the key features of EBS (Figure 3).
The phenotype of these mice strongly hinted that EBS could
indeed arise from mutations affecting the protein-coding
sequence of either K14 or K5 (Vassar et al., 1991). This pos-
sibility was further supported by publications that had described
defects in keratin IF network architecture in basal keratino-
cytes from individuals with EBS, in the epidermis in situ
(Haneke and Anton-Lamprecht, 1982; Anton-Lamprecht,
1983; Ito et al., 1991), as well as in ex vivo culture (Kitajima
et al., 1989). Such mutations were indeed found shortly
thereafter, initially in K14 (Bonifas et al., 1991; Coulombe
et al., 1991a) and later on in K5 (Lane et al., 1992), in the
genome of individuals with EBS.
In addition to providing key clue about the genetic basis of
EBS, the characterization of the first cohort of transgenic
mouse lines with tissue-specific expression of K14 deletion
mutants (Coulombe et al., 1991b; Vassar et al., 1991) suggested
a biological framework for many heretofore misunderstood
features of EBS (Coulombe et al., 2009). First, mutations
mapping to the a-helical rod domain of keratin can elicit the
formation of aggregates of amorphous proteins in the cy-
toplasm in addition to dominantly disrupting filament structure
(Coulombe et al., 1991b; Vassar et al., 1991; Fuchs et al.,
1992). Such aggregates are diagnostic for the most severe
form of EBS, i.e., EBS-DM (see Table 1), and are immuno-
positive for K5 and K14 (Coulombe et al., 1991a; Ishida-
Yamamoto et al., 1991). Second, onset of disease occurs at
birth or shortly thereafter, reflecting in part the embryonic
onset of K5 and K14 gene expression (Kopan and Fuchs,
1989; Byrne et al., 1994) along with the protected environ-
ment experienced by the human fetuses up until birth. Third,
the broad range of clinical severity typifying EBS in humans
can be mimicked in mouse skin tissue by expressing K14
mutants having either a mild, moderate, or severe impact on
keratin IF assembly in vitro (Coulombe et al., 1991b). This
finding helped dismiss the idea that variants such as EBS-DM
and EBS-loc (Table 1) had a distinct etiology. Fourth, the
ability of blisters to heal leaving no scar distinguishes EBS
from the junctional and dystrophic forms of EB (Fine et al.,
2000, 2008; Paller, 2004). From the observation that the
wound-inducible keratins 6, 16, and 17 (K6, K16, and K17)
are induced in keratinocytes populating the margins of
epidermal lesions, it has been suggested that these keratins
could compensate for the cellular fragility fostered by K5 or
K14 mutants, allowing for normal epithelialization to occur
(Coulombe et al., 1991b). Fifth, this initial set of mouse
models suggested that similar defects in other keratin proteins
should elicit analogous deficiencies in the relevant epithelial
cell types. This was later shown via the tissue-specific
expression of a deletion mutant of K10, a keratin expressed
in terminally differentiating keratinocytes of the epidermis
and related cornifying epithelia (Fuchs and Green, 1980;
Woodcock-Mitchell et al., 1982), in transgenic mice (Fuchs
et al., 1992). These mice exhibited trauma-induced cell
fragility in the suprabasal portion of epidermis, in a manner
that proved analogous to the human condition epidermolytic
hyperkeratosis. Mutations in the K1 and K10 genes were later
found in patients with this condition (Cheng et al., 1992;
Chipev et al., 1992; Rothnagel et al., 1992).
The cell fragility that typifies EBS largely corresponds to a
‘‘loss-of-keratin-function’’ phenotype, as mice homozygous null
for K14 (Figure 3), K5, or plectin display the key features of EBS
(with accompanying muscle defects in the case of plectin;
Table 1). The lesser degree to which the esophagus is affected
relative to the epidermis in newborn K14-null mice correlates
with higher levels of K15, a type I keratin related to K14, in this
tissue (Lloyd et al., 1995). The presence of small amounts of K15
also likely accounts for the markedly more severe blistering of
skin, and earlier death, in K5-null mice relative to K14-null mice
(Lloyd et al., 1995; Peters et al., 2001; Kerns et al., 2007). A
compensatory role for K15 was also proposed based on
studies of individuals with EBS, whose genome bear the
equivalent of a K14-null mutation (Chan et al., 1994a;
www.jidonline.org 767
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Jonkman et al., 1996). Later on, the targeted expression of
K16, another type I keratin homologous to K14, in basal
keratinocytes of the epidermis was shown to markedly
attenuate skin blistering and prevent neonatal death in K14-null
mice (Paladini and Coulombe, 1999). Such findings helped
foster the notion that highly homologous keratins are partially
redundant in their structural support role in vivo, and paved
the way for a search for small molecules that would, upon
topical application, provide therapeutic relief as a result of
the selective induction of a compensatory program of gene
expression (see below).
GENOTYPE–PHENOTYPE CORRELATIONS IN EBS: FROM
THE BENCH TO THE BEDSIDE AND BACK
A comprehensive and useful database of human keratin
mutations, and associated diseases, is maintained at Singa-
pore’s Bioinformatics Institute (see www.interfil.org and
Szeverenyi et al., 2008). K5 and K14 mutations account for
439% of all keratin disease–associated mutations character-
ized thus far (450 out of 1,143 reports), and together they are
second only to mutations in LMNA, the gene encoding
lamins A and C (nuclear IF proteins), for disease-causing
mutations in an IF protein–encoding gene . Mutations in K5 or
K14 account for the vast majority of EBS cases, with only a
small (although biologically significant) fraction of cases
involving mutations in genes encoding IF-associated proteins
(plectin, integrins, and collagen XVII; see Fine et al., 2008).
Most of the EBS-causing mutations occurring in K5 (486%)
and K14 (487%) are dominantly acting missense alleles, and
they are distributed across much of the sequences of the
corresponding protein products (Figure 4). This said, the
majority of these mutations alter amino-acid residues located
within the central a-helical rod domain of K5 and K14
(Figure 4), known to have a crucial role toward the assembly
and structure of keratin filaments (Fuchs and Cleveland,
1998; Omary et al., 2004; Coulombe et al., 2009).
Basic principles could readily be drawn as additional
reports of EBS-causing mutations came to the fore (Epstein,
1992; Coulombe and Fuchs, 1993; Leigh and Lane, 1993),
and are affirmed nowadays by surveying the Singapore database.
For EBS-loc, EBS-gen, and EBS-DM, a strong concordance exists
between the position and nature of the mutation in the target
keratin protein, the extent to which it disrupts keratin IF
assembly and structure in established assays, and the severity
of clinical presentation (Chan et al., 1993, 1994b; Letai et al.,
1993; Morley et al., 1995, 2003; Gu and Coulombe, 2005).
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Figure 4. Distribution of mutations in keratin 5 (K5) and keratin 14 (K14) according to epidermolysis bullosa simplex (EBS) variants. The EBS-causing
mutations that are available (September 2011) from the intermediate filament (IF) database (http://www.interfil.org; see Szeverenyi et al., 2008) are mapped to
the secondary structure of K5 and K14 protein. Helix boundary motifs (green bars), as defined by Steinert et al. (1993), correspond to 15–20 residue segments that
are very highly conserved across keratins and all other IF proteins. Trigger motifs (orange bars) are sequences capable of nucleating the formation of coiled-coil
dimers (Wu et al., 2000). The Arg125 mutation hot spot in K14 (Coulombe et al., 1991a) is indicated in red. This schematic representation does not convey the
frequency of mutations at any of the shown sites. See Table 1 for abbreviations and text for further details.
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Corollary to this notion, the nature of the mutation affecting
either K5 or K14 usually defines the sensitivity threshold that
the epithelium displays toward frictional trauma, thereby
contributing to whether the symptoms are ‘‘local’’ (e.g., EBS-
loc) or ‘‘generalized’’ (e.g., EBS-gen and EBS-DM). Mutations
altering highly conserved residues located within the short
and highly conserved sequence segments located at the
beginning and the end of the central rod domain, in either
K5 or K14, are often associated with EBS-DM (Figure 4).
Furthermore, twice as many cases of EBS-DM have been traced
to mutations in K14 rather than in K5 (n¼ 106 vs. n¼43,
respectively), reflecting the presence of a ‘‘mutational hot
spot’’ in codon 125 in the highly conserved segment within
subdomain 1A, which normally encodes an arginine residue
(Coulombe et al., 1991a; Fuchs and Coulombe, 1992; Stephens
et al., 1993; Figure 4). The very high frequency of mutations
at codon 125 of K14 (B29% of all reported mutations in
K14), and the corresponding (conserved) codon in other type I
keratins and even non-keratin IF proteins (Omary et al.,
2004; Szeverenyi et al., 2008), likely results from deamina-
tion of methylated cytosine occurring in the context of a CpG
dinucleotide. The latter represents the most frequent mechan-
ism causing mutations in the human genome (Cooper and
Youssouffian, 1988). Several lines of evidence underscore the
crucial role of this specific arginine residue in keratin IF
assembly and function (Coulombe et al., 1991a; Letai et al.,
1993; Ma et al., 2001; Werner et al., 2004).
Conversely, the mildest variant of EBS, EBS-loc, often
involves missense mutations affecting amino acids located in
the non-helical ‘‘head’’ and ‘‘linker’’ domains, particularly
K5 (Figure 4). The primary structure of these domains is less
well conserved than that of the helix boundary motifs and
other a-helical segments of the central rod domain (Parry,
2005). Mutations in these domains are generally less conse-
quential for IF assembly and function (Hatzfeld and Weber,
1991; Letai et al., 1992, 1993; Chan et al., 1993, 1994b).
Why the analogous head and linker regions of K14 are not as
frequently targeted for mutation as they are in K5 is unclear
(Figure 4). One possibility is that such mutations might
behave recessively (Hovnanian et al., 1993; Szeverenyi et al.,
2008). Another likely factor is the presence of K15 in basal
keratinocytes (Lloyd et al., 1995). Although not sufficient to
prevent the consequences of severe K14 mutations, the
presence of K15 might ameliorate subtle K14-generated
defects in the IF network of basal keratinocytes.
EBS-gen, which is intermediate in severity between EBS-
loc and EBS-DM, is also frequently associated with mutations
in the helix-initiation and helix-termination motifs, but it also
shows a greater frequency of mutations mapping elsewhere
in the rod domain, relative to EBS-DM. Another mutation bias
worth mentioning is the strong association between muta-
tions mapping to the non-helical head and tail domains of K5
protein with, respectively, the ‘‘non-classical’’ EBS with
mottled pigmentation and EBS-migratory variants (Table 1).
Although the analysis of phenotype–genotype correlation
reported here is heavily emphasized on ‘‘mutation location’’
in either K5 or K14, the nature of the mutation at any given
site on these two proteins also can weigh very heavily on
the consequences for overall biological function and disease
presentation.
The presence of cytoplasmic aggregates containing mis-
polymerized mutant keratin proteins, a defining characteristic
of EBS-DM (Table 1), may contribute to the pathophysiology
at the cellular and tissue levels. Mice made to express
aggregation-prone K14 mutants (Coulombe et al., 1991b;
Vassar et al., 1991; Cao et al., 2001) exhibit an earlier onset
of disease, more severe blistering, and die earlier than
K14-null mice (Lloyd et al., 1995). Akin to this, the EBS
phenotype exhibited by individuals null for K14 is milder
than autosomal-dominant cases of EBS-DM (Chan et al.,
1994a; Rugg et al., 1994; Jonkman et al., 1996). Conceivably,
the failure of the misfolded protein response to resolve these
aggregates may lead to cellular and tissue stress (D’Alessan-
dro et al., 2002; Liovic et al., 2008; Loffek et al., 2010) and
this could in turn impact the pathophysiology of EBS and
related conditions. Such aggregates of mispolymerized IF
proteins are characteristic of many additional disorders caused
by mutations in genes encoding non-keratin IF proteins (Omary
et al., 2004; Szeverenyi et al., 2008).
THE POST-EBS ERA: KERATIN PROTEINS FULFILL
MULTIPLE FUNCTIONS IN SKIN EPITHELIA
A wealth of evidence supports the view that the fragility state
of basal keratinocytes accounts for the production of skin
blisters in individuals with EBS, reflecting a loss of epidermal
integrity following incipient mechanical trauma. This includes
substantive pathophysiological findings obtained from the
analysis of individuals with EBS or relevant mouse models of
this condition (cf. above), along with a more detailed, and
more recent, set of studies assessing the properties of mutant
keratin–expressing epithelial cells in culture (Beil et al.,
2003; Russell et al., 2004; Lulevich et al., 2010) and
mutant keratin–containing filaments in vitro (Ma et al.,
2001; Gu and Coulombe, 2005). This role, referred to as
structural support (Table 2), has since then been extended
to virtually all keratins expressed in other epithelial
settings and to all major classes of IF polymers, including
the nuclear lamins (Lammerding et al., 2004; Kreplak and
Fudge, 2007).
Further efforts toward the creation and characterization of
transgenic mouse models alongside the study of individuals
with keratin-based diseases together have (yet again) led to
the discovery of several novel functions for keratin proteins in
skin epithelia (Table 2). A novel function so far evidenced for
K10 and K17 relates to the regulation of cell and tissue
growth in the epidermis and hair follicles. Thus, dominantly
acting mutations in either K10 or its partner K1 cause epi-
dermolytic hyperkeratosis, a condition typified by the fragility
of suprabasal keratinocytes, hyperplasia in the basal com-
partment of epidermis, and hyperkeratosis (Omary et al.,
2004; Szeverenyi et al., 2008). Nullifying the K10 gene
results in hyperproliferation in the basal layer of epidermis
(Reichelt and Magin, 2002) and sebaceous glands (Reichelt
et al., 2004) in mouse, in the absence of any sign of fragility
in suprabasal epidermal keratinocytes (Reichelt and Magin,
2002; Gu and Coulombe, 2007). Together, these human and
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mouse findings point to a role for K10, which is expressed
postmitotically (Figure 1), in regulating the rate of prolifera-
tion in the basal layer. The mechanism underlying this
remarkable phenotype is not clear at present (Reichelt and
Magin, 2002; Chen et al., 2006; Paramio et al., 2007).
K17 fosters epithelial growth in multiple settings in skin
tissue, whether healthy, injured, or diseased (Table 2). Mediated
in part by its ability to interact with and presumably sequester
14-3-3s (stratifin) in a phosphorylation-dependent manner,
K17 participates in the stimulation of protein synthesis and
epithelial cell growth occurring in wound-proximal kerati-
nocytes following injury to the epidermis (Kim et al., 2006;
Kim and Coulombe, 2010). In anagen-stage hair follicles, K17
promotes maintenance of growth in part by antagonizing
tumor necrosis factor-a signaling toward apoptosis (Tong and
Coulombe, 2006), an effect that could involve the sequestra-
tion of the adaptor protein TRADD (Inada et al., 2001).
Finally, there is evidence that K17 accelerates the onset
of basaloid skin tumors, in which it is faithfully expressed
(Markey et al., 1992), by promoting keratinocyte proliferation
correlating with the expression of proinflammatory and/or
mitogenic cytokines and chemokines in keratinocytes (De-
Pianto et al., 2010). The latter finding is captivating in light of
the implication of specific single-nucleotide polymorphisms
affecting the coding sequence of K5 and enhancing the
risk of developing basal cell carcinoma in humans (Stacey
et al., 2009). Besides, a recent genome-wide screen has
implicated K6, K16, and K17 in a genetic network defining
the key inerrelationship between barrier function, inflam-
mation, and tumor susceptibility in mouse skin (Quigley
et al., 2009).
In keeping with the theme of chemokines, Roth et al.
(2009) have reported on an increased density of Langerhans
cells in mice null for K5, and in individuals with EBS resulting
from mutations at the K5 locus. This phenomenon, which
does not occur in K14-null mouse skin or in K14 mutation–-
related cases of EBS, correlates with an upregulation in
chemokines (e.g., CCl2, CCL19, and CCL20) known to attract
Langerhans cell precursors to the skin (Roth et al., 2009;
Lu et al., 2007), and otherwise adds to the emerging concept
that keratins may act as key immune modulators in the skin
(DePianto et al., 2010).
Keratin 6, which along with K16 and K17 is rapidly
induced in wound-proximal, surviving keratinocytes follow-
ing injury to the skin (Paladini et al., 1996), was shown years
ago to be essential to the maintenance of cell integrity in
keratinocytes migrating into the wound (Wong and Cou-
lombe, 2003). Although more fragile, K6-null mouse skin
keratinocytes migrate faster than their wild-type counterpart
in mechanically softer settings, such as skin explant culture
and primary culture. This surprising property has been linked
to the ability of K6 to directly bind to, and negatively regulate,
Src kinase, a key driver of cell migration (J Rotty and PA
Coulombe, unpublished data). Thus, K6, and keratin-associated
Table 2. Established roles of keratin proteins in skin epithelia
Description of
functional role Keratin(s)
Biological
context Comments
Structural support All Epidermis and
hair follicles
Proper structure and organization of intracellular keratin filaments is essential to withstanding frictional
and mechanical stresses (Vassar et al., 1991; Coulombe et al., 1991b).
Cell and tissue
growth
K10 Epidermis In mouse, loss of K10 results in enhanced proliferation in the epidermis, akin to what occurs in
epidermolytic hyperkeratosis. The mechanism(s) involved remains to be defined, but might well be non-
cell autonomous (Reichelt and Magin, 2002).
K17 Hair follicle
cycling
In mouse, loss of K17 results in premature entry into catagen, owing in part to enhanced TNF-a signaling
and apoptosis. A potential mechanism is the interaction with, and negative regulation of, the adaptor
protein TRADD (Tong and Coulombe, 2006; Inada et al., 2001).
K17 Wound edge K17 participates in the increase occurring in the size of keratinocytes, whereas in primary culture and at
the wound edge in embryonic ectoderm by stimulating protein synthesis, an event that depends in part on
its phosphorylation-dependent interaction with 14-3-3s (stratifin) (Kim et al., 2006).
Skin pigmentation K1, K2,
K5
Epidermis A heroic random mutagenesis screen revealed a role for K1 and K2 in skin pigmentation in mouse. In
addition, EBS-MP and Dowling-Degos disease (cf. Table 1) are caused by mutations at the K5 locus in
humans (Uttam et al., 1996; Betz et al., 2006; Fitch et al., 2003).
Keratinocyte
migration
K6 Wound edge In addition to providing structural support in keratinocytes migration into wound site, K6 negatively
regulates their migration speed via a direct, and inhibitory, interaction with Src kinase. The latter is
believed to foster the cohesive migration of keratinocytes as a cellular sheet (J Rotty and PA Coulombe,
unpublished data).
Langerhans cell
density
K5 Epidermis In mouse, loss of K5 results in an increased Langerhans cell density in the epidermis. The same
phenomenon occurs in EBS patients with K5 mutations, specifically. The mechanism is unknown, but
likely involve elevated expression of select chemokines acting on DC precursors (Roth et al., 2009).
Immunomodulation K17 Skin cancer In mouse, loss of K17 causes a delay in the onset of basaloid skin tumors and the extent of phorbol
ester–induced dermatitis, correlating with reduced keratinocyte proliferation and a global switch from a
Th1/Th17- dominated to a Th2-dominated immune cytokine/chemokine profile. Mechanism(s) unknown
(DePianto et al., 2010).
Abbreviations: DC, dendritic cell; EBS, epidermolysis bullosa simplex; EBS-MP, EBS with mottled pigmentation; Th1, T helper type 1; TNF-a, tumor necrosis
factor-a.
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proteins such as plakoglobin and plectin (Yin et al., 2005;
Osmanagic-Myers et al., 2006), may promote the mainte-
nance of intercellular cohesiveness in migrating sheets of
keratinocytes by scaling back the extent to which a potentially
oncogenic signaling protein, namely Src, is activated during
tissue repair.
Pigmentation represents yet another key property of the
skin potentially affected by keratin proteins. The evidence
supporting this newly defined role has been reviewed (Gu
and Coulombe, 2007), and hence only three elements re-
levant to other sections of this text will be mentioned here.
First, Uttam et al. (1996) discovered that a rather peculiar
missense mutation in the head domain of K5, Pro24-4Leu,
causes EBS with ‘‘mottled pigmentation’’ (Table 1). Several
additional cases of EBS with mottled pigmentation have since
then been traced to the same K5 allele (Szeverenyi et al.,
2008), and to distinct mutations in K5 (1649delG; Horiguchi
et al., 2005) or K14 (Met119-4Thr; Harel et al., 2006). The
1649delG allele of K5 can also result in EBS migratory
(Table 1), and this too is characterized by the appearance of
hyperpigmented or hypopigmented skin patches in adults
(Gu et al., 2003). Second, a very rare condition typified
by reticulate hyperpigmentation and dark hyperkeratotic
papules in skin flexural regions, Dowling-Degos disease
(Table 1), has been linked to K5 haploinsufficiency (Betz
et al., 2006). Third, dominantly acting missense alleles in K2
and K1 elicit a dark skin phenotype, as discovered in a
random mutagenesis screen designed to identify novel deter-
minants of coat color in mouse (Fitch et al., 2003; McGowan
et al., 2006). Expression of these K2 and K1 alleles in mouse
skin reproduces the keratinocyte fragility and epidermolytic
hyperkeratosis-like manifestations associated with similar
mutations in the human orthologs. No mechanism has been
established to account for these pigmentation phenotypes,
although there is preliminary evidence pointing to an
interaction between K5 and components of microtubule-
dependent motors, which are involved in melanin pigment
transport (Betz et al., 2006; Gu and Coulombe, 2007).
Finally, select clinical attributes of EBS still have no sound
biological basis. Topping the list of such attributes are two
frequent occurrences: enhanced frequency of skin blistering
during the warm season and age-related improvement in
clinical symptoms (Fine et al., 2000, 2008; Paller, 2004).
Although experimental evidence is still lacking, one possibility
is that conditions that activate the heat shock/stress response
may alter the aggregates of misassembled keratins (Omary
et al., 2004; Loffek et al., 2010). Understanding the basis for
these peculiar clinical features may lead to new insights into
keratin regulation and function, epithelial biology, and in-
novative ideas for the treatment of EBS.
DEVISING AN EFFECTIVE THERAPY FOR EBS:
CHALLENGES AND OPPORTUNITIES
Elucidating the etiology and gaining a better understanding of
the pathophysiology of EBS has undoubtedly resulted in more
extensive and effective means of prenatal and postnatal
genetic testing and counseling options (Holbrook et al., 1992;
Rugg et al., 2000; Pfendner et al., 2003). However, therapeutic
options available to patients suffering from this chronic
debilitating disorder are still lacking. Notwithstanding its
significantly milder nature relative to the other subtypes of EB
diseases, and in spite of the age-related improvement in the
severity of its symptoms, EBS imposes significant restrictions
and affects lifestyle well into adulthood. Yet, the standard of
care for EBS, i.e., minimizing trauma and preventing infections
in healing blisters, remains largely preventive and palliative
in spite of two decades of very substantive progress about its
genetic and biological underpinnings. The broad spectrum of
mutations occurring in either K5 or K14 along with their
dominant mode of action, the intrinsically high cell turnover
rate taking place in the epidermis, and the low incidence of
EBS, an orphan disease, in the human population all contribute
to the challenge of devising safe, effective, and long-lasting
therapies. The relatively few formalized efforts to test therapies
for EBS in human subjects have yielded inconclusive results
(Langan and Williams, 2008), or need to be scaled up.
There is now compelling experimental evidence, obtained
in the setting of mouse skin tissue in vivo, confirming the
prediction that the impact of strong dominant-negative
mutant keratin proteins can be reversed as expression of the
corresponding wild-type protein (or a functional equivalent)
is titrated back in epidermal basal cells (Cao et al., 2001).
This is also generally consistent with a phenomenon of
‘‘revertant mosaicism’’ noted in the skin of individuals with
EBS in which a ‘‘second hit’’ (e.g., a frameshift mutation)
in the original mutant K14 allele generates the equivalent of
a null allele (Smith et al., 2004) or a ‘‘corrected’’ allele
(Schuilenga-Hut et al., 2002), thus negating the impact of an
otherwise strong dominant-negative mutation (also see
D’Alessandro et al., 2011). The elegant study by Cao et al.
(2001) also showed that wild-type keratinocytes have a
growth advantage over those expressing mutant keratin in
skin epithelia in vivo, a finding with obvious implications for
gene therapy.
Considerable progress has been made in recent years with
regard to strategies that specifically target, or interfere with,
disease-causing keratin alleles in keratinocytes (Lewin et al.,
2005; McLean and Moore, 2011). Various allele-specific
strategies are being tested, including gene targeting (Petek
et al., 2010) and trans-splicing (Wally et al., 2008, 2010),
which are directed at the relevant genomic DNA locus, and
thus offer the distinct advantage of being potentially curative,
and alternatively gene silencing (Atkinson et al., 2011), which
targets the relevant mRNA and therefore would necessitate
continuous treatment. A distinct strategy is to attempt to in-
tervene at the protein level (Kerns et al., 2007, 2010). Thus,
topical application of the natural product sulforaphane
significantly ameliorates the skin blistering and survival of
K14-null mice, but not K5-null ones, correlating with its
ability to induce the K16 and K17 expression (Kerns et al.,
2007). Besides, there is evidence that stimulation of protein
homeostasis pathways lessens keratin mutant protein aggre-
gation in EBS keratinocyte cell lines (Lee et al., 2008; Chamcheu
et al., 2010, 2011; Loffek et al., 2010). Finally, there are reports
showing that injection of botulinum toxin (‘‘Botox’’) in plantar
skin ameliorates the blistering and diminishes pain in individuals
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with EBS and pachyonychia congenita (Swartling et al., 2010).
These encouraging results notwithstanding, there is much work
to be done as one attempts to export and translate encouraging
results obtained in virally transformed human keratinocyte
cell lines or transgenic mouse models to human skin.
PRIORITIZING FUTURE EFFORTS IN THIS FIELD
There are multiple issues of significant interest and impor-
tance in the triad formed by keratin genes and their proteins,
skin epithelia, and genodermatoses. However, some stand
out, and they are as follows. First, we sorely need a reliable,
atomic-resolution model for the structure of IFs. Second, we
need to better understand the mechanisms regulating keratin
filament assembly in their natural setting in vivo. Third, we
need to better understand the relationship between keratin
filament and mechanical resilience, and whether the cell
fragility that is seen in conditions such as EBS is entirely the
result of defects in cellular mechanics. Related to this, we
need to devise reliable biomarkers reporting on cell fragility.
Fourth, we need ‘‘actionable findings’’ that lead to a genuine
clinical improvement in patients suffering from EBS and other
keratin-based genodermatoses. As a final point, perhaps, we
need to understand the rationale for the remarkable diversity
of keratin proteins, and the differentiation- and context-
dependent nature of their expression in epithelia.
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